Literature DB >> 28334939

Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.

Duygu Tosun1, Susan Landau2, Paul S Aisen3, Ronald C Petersen4, Mark Mintun5, William Jagust2, Michael W Weiner1.   

Abstract

See Vandenberghe and Schaeverbeke (doi:10.1093/awx065) for a scientific commentary on this article. A long-term goal of our field is to determine the sequence of pathological events, which ultimately lead to cognitive decline and dementia. In this study, we first assessed the patterns of brain tau tangle accumulation (measured with the positron emission tomography tracer 18F-AV-1451) associated with well-established Alzheimer's disease factors in a cohort including cognitively healthy elderly individuals and individuals at early symptomatic stages of Alzheimer's disease. We then explored highly associated patterns of greater 18F-AV-1451 binding and increased annualized change in cortical amyloid-β plaques measured as florbetapir positron emission tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to what extent these multimodal pattern associations explained the variance in cognitive performance and clinical outcome measures, independently and jointly. We found that: (i) 18F-AV-1451 positron emission tomography retention was differentially associated with age, and cross-sectional florbetapir positron emission tomography retention, but not with years of education, gender, or APOE genotype; (ii) increased annualized change in florbetapir retention, antecedent to 18F-AV-1451 positron emission tomography scans, in the parieto-temporal and precuneus brain regions was associated with greater 18F-AV-1451 PET retention most prominently in the inferior temporal and inferior parietal regions in the full cohort, with florbetapir positive/negative-associated variability; and (iii) this 18F-AV-1451 positron emission tomography retention pattern significantly explained the variance in cognitive performance and clinical outcome measures, independent of the associated antecedent increased annualized change in florbetapir positron emission tomography retention. These findings are in agreement with the pathology literature, which suggests that tau tangles but not amyloid-β plaques correlate with cognition and clinical symptoms. Furthermore, non-local associations linking increased amyloid-β accumulation rates with increased tau deposition are of great interest and support the idea that the amyloid-β pathology might have remote effects in disease pathology spread potentially via the brain's intrinsic connectivity networks.
© The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; amyloid-β; positron emission tomography; tau

Mesh:

Substances:

Year:  2017        PMID: 28334939     DOI: 10.1093/brain/awx046

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

1.  Cerebrospinal fluid Aβ42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability.

Authors:  Karin L Meeker; Beau M Ances; Brian A Gordon; Cort W Rudolph; Patrick Luckett; David A Balota; John C Morris; Anne M Fagan; Tammie L Benzinger; Jill D Waring
Journal:  Neurobiol Aging       Date:  2020-11-02       Impact factor: 4.673

2.  Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?

Authors:  Polyxeni Stamati; Vasileios Siokas; Athina-Maria Aloizou; Emmanouil Karampinis; Stylianos Arseniou; Valerii N Rakitskii; Aristidis Tsatsakis; Demetrios A Spandidos; Illana Gozes; Panayiotis D Mitsias; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  J Mol Neurosci       Date:  2019-07-02       Impact factor: 3.444

3.  Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.

Authors:  Hee Jin Kim; Seongbeom Park; Hanna Cho; Young Kyoung Jang; Jin San Lee; Hyemin Jang; Yeshin Kim; Ko Woon Kim; Young Hoon Ryu; Jae Yong Choi; Seung Hwan Moon; Michael W Weiner; William J Jagust; Gil D Rabinovici; Charles DeCarli; Chul Hyoung Lyoo; Duk L Na; Sang Won Seo
Journal:  JAMA Neurol       Date:  2018-08-01       Impact factor: 18.302

Review 4.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

5.  Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.

Authors:  Sandhitsu R Das; Long Xie; Laura E M Wisse; Ranjit Ittyerah; Nicholas J Tustison; Bradford C Dickerson; Paul A Yushkevich; David A Wolk
Journal:  Neurobiol Aging       Date:  2018-02-09       Impact factor: 4.673

Review 6.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

Review 7.  A clinicopathological approach to the diagnosis of dementia.

Authors:  Fanny M Elahi; Bruce L Miller
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

8.  Subthreshold Amyloid Predicts Tau Deposition in Aging.

Authors:  Stephanie L Leal; Samuel N Lockhart; Anne Maass; Rachel K Bell; William J Jagust
Journal:  J Neurosci       Date:  2018-04-23       Impact factor: 6.167

9.  Financial Capacity and Regional Cerebral Tau in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia.

Authors:  Christopher Gonzalez; Nicole S Tommasi; Danielle Briggs; Michael J Properzi; Rebecca E Amariglio; Gad A Marshall
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

10.  Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.

Authors:  Murat Bilgel; Yang An; Jessica Helphrey; Wendy Elkins; Gabriela Gomez; Dean F Wong; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.